



La Presidenta de la Real Academia de Medicina de la Comunidad Valenciana tiene el honor de invitarle a la Mesa Redonda, perteneciente al **Ciclo: Debates en Salud Pública 2020**, sobre el nuevo coronavirus:

**“PERSPECTIVAS SOBRE EL RETO DEL NUEVO
CORONAVIRUS”**

Perspectiva clínica: **COVID-19**

José López Aldeguer

Servicio de Medicina Interna

Hospital La Fe

Agenda

- Antecedentes históricos
- Sintomatología clínica
- Diagnóstico
- Tratamientos
- Prevención


... antecedentes

Coronavirus

Causantes de cuadros respiratorios...

- *Leves o moderados*
 - 229E, NL63, OC43, HKU1
- *Graves*
 - SARS-CoV
 - MERS-CoV

... y ahora
- *SARS-CoV19 (causante del COVID)*



**Producido por un Betacoronavirus,
linaje B**

8.098 personas afectadas



**774 muertes
Índice de letalidad: 10%**

**Síndrome respiratorio agudo severo
Incubación 2-7 días (máx 14)**

**Transmisión persona a persona por
contacto cercano a través de gotitas
respiratorias
62-79% en recintos asistenciales
22-39% transmisión entre
familiares**

CDC

Primer brote: SARS-CoV 2002-2003



**Producido por un
Betacoronavirus, linaje C**



**2.424 casos (2.102 casos solo
en Arabia Saudita)**

**858 muertes (780 en AS)
Índice de letalidad: 35%**


**Síndrome respiratorio de medio
oriente (enf. resp. grave)
Incubación 5-6 días (máx 14)**

**Transmisión persona a persona por
contacto cercano a través de gotitas
respiratorias**
43.5–100% en recintos asistenciales
13–21% transmisión entre familiares

Segundo brote: MERS-CoV 2012-



CoV. Salto interespecies




Manifestaciones clínicas

COVID-19. Síntomas

Similares a una gripe:

- *Tos seca*
- *Mialgias*
- *Fiebre*
- *Fatiga*
- *Disnea*



Complicaciones

- *Neumonía*
- *Insuf. Respiratoria*
- *SDRA*
- *Shock*
- *Fracaso multiorgánico*

Clinical features of patients infected with 2019 novel coronavirus in

The NEW ENGLAND JOURNAL of MEDICINE

Chaolin Huang*, Yeming Wang*, Xi
Zhenshun Cheng, Ting Yu, Jiaan Xia,
Guangfa Wang, Rongmeng Jiang, Zi

Summary

Background A recent cluster
2019 novel coronavirus (2019-

BRIEF REPORT

First Case of 2019 Novel Coronavirus in the United States

ORIGINAL ARTICLE

Early Transmission Dynamics in Wuhan, of Novel Coronavirus–Infected Pneumonia

Qun Li, M.Med., Xuhua Guan, Ph.D., Peng Wu, Ph.D., Xiaoye Wang
Lei Zhou, M.Med., Yeqing Tong, Ph.D., Ruiqi Ren, M.Med.,
Kathy S.M. Leung, Ph.D., Eric H.Y. Lau, Ph.D., Jessica Y. Wong, F

Click here to try the
New PubMed!



An updated version of PubMed is now available.
Come see the new improvements to the interface!

Format: Summary ▾ Sort by: Most Recent ▾ Per page: 100 ▾

Send to ▾ Fil

Search results

Items: 82

★ Did you mean: [corvid](#) (217 items)

[18F-FDG PET/CT findings of COVID-19: a series of four highly suspected](#)

1. cases

February 24, 2020

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Zunyou Wu, MD, PhD¹; Jennifer M. McGoogan, PhD¹

Age distribution (N=44 672)

- ≥80 years: 3% (1408 cases)
- 30-79 years: 87% (38 680 cases)
- 20-29 years: 8% (3619 cases)
- 10-19 years: 1% (549 cases)
- <10 years: 1% (416 cases)

Spectrum of disease (N=44 415)

- Mild: 81% (36 160 cases)
- Severe: 14% (6168 cases)
- Critical: 5% (2087 cases)

JAMA Network

JAMA® Search All Enter Search Term

February 24, 2020

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Zunyou Wu, MD, PhD¹; Jennifer M. McGoogan, PhD¹



Health care personnel infected

- 3.8% (1716 of 44 672)
- 63% in Wuhan (1080 of 1716)
- 14.8% cases classified as severe or critical (247 of 1668)
- 5 deaths

Case-fatality rate


- 2.3% (1023 of 44 672 confirmed cases)
- 14.8% in patients aged ≥ 80 years (208 of 1408)
- 8.0% in patients aged 70-79 years (312 of 3918)
- 49.0% in critical cases (1023 of 2087)

COVID-19: Neumonía (días 8 y 11 de síntomas)




Zhu, N et al. NEJM 2020

COVID-19: Neumonía (varón, día 15)




Huang C, et al. Lancet 2020

COVID-19: Neumonía (mujer día 8...)




COVID-19: Neumonía (... y días 12)



Huang C, et al. Lancet 2020

COVID-19: Neumonía (primer caso en USA, día 10)



COVID-19. Factores mal pronóstico

- Edad (avanzada)
- Sexo (varón)
- Comorbilidades

Diagnóstico

COVID-19: Diagnóstico

- Epidemiológico / Clínico
- Microbiológico (PCR en tiempo real)
 - PCR de *screening* positiva y PCR de confirmación en un gen alternativo también positiva

Tratamiento

COVID-19. Tratamiento

Principios generales

1. No se conoce un tratamiento eficaz y seguro
2. Existen varios ensayos clínicos en marcha, pero aún sin resultados
3. Puede afectar a adultos jóvenes c/s comorbilidades
4. La gravedad de la infección es muy variable, desde formas asintomáticas, infecciones de vías respiratorias altas leves y neumonías graves
5. La aparición de insuficiencia respiratoria parece producirse en torno al octavo día
6. La coinfección bacteriana es infrecuente. Puede haber una coinfección viral mixta por compartir mecanismos de transmisión similares

COVID-19. Tratamiento farmacológico

Situación clínica	Fármaco
Asintomáticos (sin comorbilidades)	Sintomático si procede (no antivirales)
Infección leve <ul style="list-style-type: none">• IRS / Rx normal,• > 60 años (sin comorbilidades),• Presencia de comorbilidades (EPOC, ECV, DM, cáncer, Hepatopatía crónica, Inmunosupresión)	Sintomático Ofrecer: Lopinavir/ritonavir
Infección grave definida por: <ul style="list-style-type: none">• Neumonía y/o• Insuficiencia respiratoria	Tratamiento de sostén. Como antiviral: - Preferente: Remdesivir - Alternativas: 1. Lopinavir/r + IFN-β1b sc 2. Lopinavir/r + IFN-α2b nebulizado

COVID-19. Otros posibles tratamientos

Fármaco o producto
Cloroquina
Favipiravir
Tocilizumab,
Baricitinib
Suero convalesciente
.../...

Coronavirus. Ensayos de tratamiento

The screenshot shows the ClinicalTrials.gov website with search results for "Interventional Studies | Coronavirus". The page displays 44 studies found, with the first two visible in a table. The table columns are Row, Saved, Status, Study Title, Conditions, Interventions, and Locations. The first study is "A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia" with a status of "Not yet recruiting" and a "NEW" tag. The second study is "SARS Coronavirus Vaccine (SARS-CoV)" with a status of "Withdrawn".

NIH U.S. National Library of Medicine
ClinicalTrials.gov

Find Studies ▾ About Studies ▾ Submit Studies ▾ Resources ▾ About Site ▾

Home > Search Results

Modify Search Start Over

44 Studies found for: **Interventional Studies | Coronavirus**

Applied Filters: **Interventional**

List By Topic On Map Search Details

Hide Filters Download Subscribe to RSS Show/Hide Columns

Showing: 1-10 of 44 studies 10 studies per page

Row	Saved	Status	Study Title	Conditions	Interventions	Locations
1	<input type="checkbox"/>	Not yet recruiting NEW	A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia	• Coronavirus	• Biological: MSCs-derived exosomes	
2	<input type="checkbox"/>	Withdrawn	SARS Coronavirus Vaccine (SARS-CoV)	• Coronavirus (SARS-CoV)	• Drug: Aluminum hydroxide	• Baylor College of Medicine - Molecular Virology and

Programac_seman...pdf Lancet.Reducing...pdf Lancet.Genomic c...pdf nejm-A Novel Cor...pdf


Mostrar todo x

Coronavirus. Ensayos con remdesivir

NIH U.S. National Library of Medicine
ClinicalTrials.gov

Find Studies ▾ About Studies ▾ Submit Studies ▾ Resources ▾ About Site ▾

Home > Search Results


[Modify Search](#) [Start Over](#) 

2 Studies found for: **remdesivir**

details

Saved	Status	Study Title	Conditions	Interventions
<input type="checkbox"/>	Recruiting NEW	Severe 2019-nCoV Remdesivir RCT	<ul style="list-style-type: none">2019-nCovRemdesivir	<ul style="list-style-type: none">Drug: RemdesivirDrug: Remdesivir placebo
<input type="checkbox"/>	Recruiting NEW	Mild/Moderate 2019-nCoV Remdesivir RCT	<ul style="list-style-type: none">2019-nCoV	<ul style="list-style-type: none">Drug: RemdesivirDrug: Remdesivir placebo

Coronavirus. Ensayos de tratamiento



Prevención

COVID19. Prevención

- Medidas de barrera (contacto y gotas)
- Fármacos
- Vacunas

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection

Emmie de Wit^{a,1} , Friederike Feldmann^b, Jacqueline Cronin^a, Robert Jordan^c, Atsushi Okumura^d, Tina Thomas^a, Dana Scott^b, Tomas Cihlar^c, and Heinz Feldmann^a

^aLaboratory of Virology, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, MT 59840; ^bRocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, MT 59840; ^cBiology Department, Gilead Sciences, Foster City, CA 94404; and ^dCenter for Infection

Vacunas contra el SARS-COV19

🕒 03 February 2020

CEPI and GSK announce collaboration to strengthen the global effort to develop a vaccine for the 2019-nCoV virus

GSK to make adjuvant technology available for the development of candidate vaccines

Oslo, Norway; London, UK

CEPI, the Coalition for Epidemic Preparedness Innovations, and GSK have announced a strategic collaboration aimed at helping the global effort to develop a vaccine for the 2019-nCoV virus.

The screenshot shows the PharmaTimes website interface. At the top is the PharmaTimes logo with 'online' underneath. To the right of the logo is a search bar with the placeholder text 'Search news, articles, experts, insights'. Below the logo is a navigation menu with links for 'Magazine', 'Web Exclusives', 'News', 'Competitions', 'Appointments', 'Jobs', and 'Business Insights'. Below the navigation menu are links for 'Webinars' and 'Thought Leadership'. At the bottom of the navigation area are links for 'Free news subscriptions' and 'Free RSS feeds'. The main content area features a large article headline: 'Gilead joins GSK, J&J in offering coronavirus vaccine options'. Below the headline is the date '5th February 2020'. On the right side of the page, there is a vertical sidebar with a graphic that says '3 weeks left to place in the' and '10 YEAR' above 'PharmaTimes CLINICAL RESEARCHER OF THE YEAR FOR THE AMERICAS'. Below the graphic is a link for 'News alerts'.

SARS-CoV19. Proyectos investigación en vacuna

Proyectos / laboratorios
Sanofi Pasteur and HHS
GeoVax and BravoVax Covid-19 vaccine
Janssen Research & Development and HHS
iBio and CC-Pharming
Coalition for Epidemic Preparedness Innovations (CEPI) and GSK
CEPI and University of Queensland
CEPI, Moderna and National Institute of Allergy and Infectious Diseases
CEPI and CureVac
Regeneron Pharmaceuticals and U.S. Department of Health and Human Services
.../...


<https://www.pharmaceutical-technology.com/features/covid-19-pharmaceutical-company-partnerships-for-coronavirus-vaccines-development/>

A modo de conclusión

Side-by-side comparison


Total cases vs total recovered patients vs total deaths.

Coronavirus: Global confirmed cases, deaths and recovered



Get the data · Created with Datawrapper

Coronavirus: Global deaths and recovered patients





Get the data · Created with Datawrapper

Most cases confined to Hubei, China

Total cases and deaths to date by location: top 10 worst affected locations.

Coronavirus: worst affected areas, by confirmed cases and deaths

- Hubei, China
- Guangdong, China
- Henan, China
- Zhejiang, China
- Heilongjiang, China
- Iran, City NA
- Other



<https://www.pharmaceutical-technology.com/special-focus/covid-19/coronavirus-covid-19-outbreak-latest-information-news-and-updates/>

Chart: pharmaceutical-technology.com • Source: John Hopkins University • Get the data • Created with Datawrapper



Jose R Arribas
@jrarribas

#COVID-19 Vs SARS & FLU 2020 02 21 Update. Most of the ? solved

Tradueix el tuit

20200221 Update

	Seasonal Flu	1918 Flu	SARS	COVID-19
R_0	1.3 (0.9-2.1) ¹	2 (1.4-2.8) ¹	2-4 ²	2-3-3.77 ^{3,4,5,6}
Incubation period (days)	2 (1-4) ⁷		4-5 ²	5 (4.1-7) ⁴
Serial interval (days)	2-4 ⁷		7-11 ²	7.5 ± 3.4 ⁵
Secondary attack rate	5-15% ⁸			?
Asymptomatic shedding before illness onset	4-48 h		No	Yes ⁹
Shedding and peak viral load (days) after symptom onset	5 (peak @ 1-3) ⁷		peak @ 10-14 ^{10,11}	0-5 ¹²
Virus in stool specimens			Yes (RNA) ¹³	Yes (RNA & Culture) ¹⁴
incubation period (days)	2 (1-4) ⁷	30%	4-5 ²	5 (4.1-7) ⁴
Serial interval (days)	2-4 ⁷		7-11 ²	7.5 ± 3.4 ⁵
Secondary attack rate	5-15% ⁸			?
Asymptomatic shedding before illness onset	4-48 h		No	Yes ⁹
Shedding and peak viral load (days) after symptom onset	5 (peak @ 1-3) ⁷		peak @ 10-14 ^{10,11}	0-5 ¹²
Virus in stool specimens			Yes (RNA) ¹³	Yes (RNA & Culture) ¹⁴
Population affected (%)	8-11% (US) 19/20 season ¹⁵	30% (worldwide) ^{16,17}	8096 (total) ¹⁸	76,727 (total) ¹⁹
Mortality (%)	0.0001-0.2235 ²⁰	2.04 ²¹ >2.5 ¹⁶ 10-20 ¹⁷	10 ²	0.2-14.8 (China) ²² 1.4 Rest of the world ¹⁷ 0.94 (IFR) ²³
Total deaths worldwide	291,243 to 645,832 ¹⁸	50-100 million ^{16,17}	774 ¹⁸	2,247 (ongoing) ¹⁹

20200221 Update

	Seasonal Flu	1918 Flu	SARS	COVID-19
R_0	1.3 (0.9-2.1) ¹	2 (1.4-2.8) ¹	2-4 ²	2-3-3.77 ^{3,4,5,6}
Incubation period (days)	2 (1-4) ⁷		4-5 ²	5 (4.1-7) ⁴
Serial interval (days)	2-4 ⁷		7-11 ²	7.5 ± 3.4 ⁵
Secondary attack rate	5-15% ⁸			?
Asymptomatic shedding before illness onset	4-48 h		No	Yes ⁹
Shedding and peak viral load (days) after symptom onset	5 (peak @ 1-3) ⁷		peak @ 10-14 ^{10,11}	0-5 ¹²
Virus in stool specimens			Yes (RNA) ¹³	Yes (RNA & Culture) ¹⁴
Population affected (%)	8-11% (US) 19/20 season ¹⁵	30% (worldwide) <small>16,17</small>	8096 (total) ¹⁸	76,727 (total) ¹⁹
Mortality (%)	0.0001-0.2235 ²⁰	2.04 ²¹ >2.5 ¹⁶ 10-20 ¹⁷	10 ²	0.2-14.8 (China) ²² 1.4 Rest of the world ¹⁷ 0.94 (IFR) ²³
Total deaths worldwide	291,243 to 645,832 ¹⁸	50-100 million ^{16,17}	774 ¹⁸	2,247 (ongoing) ¹⁹

¹ BMC Med 2009; 7:700-8.

